open access

Vol 18, No 6 (2013)
SpeciaI issue papers
Published online: 2013-11-01
Submitted: 2013-08-30
Get Citation

Improving outcomes in high-risk prostate cancer with radiotherapy

William R. Polkinghorn, Michael J. Zelefsky
DOI: 10.1016/j.rpor.2013.10.006
·
Rep Pract Oncol Radiother 2013;18(6):333-337.

open access

Vol 18, No 6 (2013)
SpeciaI issue papers
Published online: 2013-11-01
Submitted: 2013-08-30

Abstract

There have been significant improvements in the radiotherapeutic management of patients with high risk prostate cancer. Randomized trials have clearly demonstrated improved outcomes with the combination of radiotherapy in conjunction with androgen deprivation. While these trials have utilized low doses of radiotherapy in the range of 70[[ce:hsp sp="0.25"/]]Gy, recent studies have suggested that significant benefits of combined androgen deprivation therapy with dose escalated radiotherapy are also observed. The use of high radiation dose levels in the setting of high risk prostate cancer is important, and strategies which combine external beam radiotherapy with a brachytherapy boost may provide an opportunity for even greater intensification of the radiation dose to the prostate target. Systemic therapies, second generation anti-androgen therapy and novel targeted agents integrated with radiotherapy will open up new vistas and challenges for further improved outcomes in patients with high-risk disease.

Abstract

There have been significant improvements in the radiotherapeutic management of patients with high risk prostate cancer. Randomized trials have clearly demonstrated improved outcomes with the combination of radiotherapy in conjunction with androgen deprivation. While these trials have utilized low doses of radiotherapy in the range of 70[[ce:hsp sp="0.25"/]]Gy, recent studies have suggested that significant benefits of combined androgen deprivation therapy with dose escalated radiotherapy are also observed. The use of high radiation dose levels in the setting of high risk prostate cancer is important, and strategies which combine external beam radiotherapy with a brachytherapy boost may provide an opportunity for even greater intensification of the radiation dose to the prostate target. Systemic therapies, second generation anti-androgen therapy and novel targeted agents integrated with radiotherapy will open up new vistas and challenges for further improved outcomes in patients with high-risk disease.

Get Citation

Keywords

High-risk prostate cancer; External beam radiation therapy; Androgen-deprivation therapy; Anti-androgen agents; Androgen receptor

About this article
Title

Improving outcomes in high-risk prostate cancer with radiotherapy

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 18, No 6 (2013)

Pages

333-337

Published online

2013-11-01

DOI

10.1016/j.rpor.2013.10.006

Bibliographic record

Rep Pract Oncol Radiother 2013;18(6):333-337.

Keywords

High-risk prostate cancer
External beam radiation therapy
Androgen-deprivation therapy
Anti-androgen agents
Androgen receptor

Authors

William R. Polkinghorn
Michael J. Zelefsky

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl